IUGNF - Imugene talks VAXINIA MAST trial and corporate ambition

(NewsDirect)

Imugene Ltd(ASX:IMU, OTC:IUGNF) CEO Leslie Chong speaks with Proactive soon afterthe company announced it has cleared the first cohort of patients ofthe intratumoral (IT) arm of its VAXINIA metastatic advanced solidtumours (MAST) trial and is now recruiting for cohort 2 of thestudy’s IT and intravenous/IV arms. The multicenter Phase 1 MASTtrial commenced by delivering a low dose of VAXINIA to patients withmetastatic or advanced solid tumours who have had at least two priorlines of standard-of-care treatment. The City of Hope-developedoncolytic virus has been shown to shrink colon, lung, breast, ovarianand pancreatic cancer tumours in preclinical laboratory and animalmodels.

Chongsaid: “We've now seen a very significant number of patientsdosed with VAXINIA as part of the MAST study, with those patientssuffering as a result of a variety of tumour types. It's excitingthat we're getting so close to finding out the impact that thistreatment is having for these patients in need.”

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

Jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.